KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
KAZIA THERAPEUTICS LTD
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 7, 2025
$7.85+0.60 (+8.28%)
Close on Oct 19, 2026
KAZIA THERAPEUTICS LTD income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- -49290.5%
- Return on equity, FY2025
- 226.0%
Financial strength
- Current ratio
- 2.87
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 285.0%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
Valuation ratios need the share price and fill in once daily prices are connected.